ClinicalTrials.gg
CompletedNCT04063176PROFILE-MIUpdated Jun 11, 2025

Prospective Outpatient Registry of Myocardial Infarction Patients

An observational study in Myocardial Infarction, sponsored by National Research Center for Preventive Medicine. Completed. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by National Research Center for Preventive Medicine · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The investigators enrolled 160 patients who visited Moscow state outpatient clinic №9 (and its two branches) within six months after acute myocardial infarction. The enrollment lasted from 01.03.2014 to 01.07.2015. The observation period is five years. During the first year after enrollment in the study, patients had follow-up visits every two months, from second-year every six months. Analysis of the prescribed therapy and its changes was carried out by the cardiologist in the clinic for the entire observation period, taking into account the concomitant diseases /indications/contraindications. Endpoints (the death, repeated cardiovascular complications (AMI, stroke), emergency hospitalization due to worsening of the main cardiovascular disease, the appearance of clinically significant cardiac arrhythmias, invasive interventions) were defined during out-patient visits and telephone contact

02

Conditions studied

  • Myocardial Infarction

Keywords

  • myocardial infarction, registry
03

In context

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

This study's enrollment of 160 is below the median of 568 across 814 observational studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

National Research Center for Preventive Medicine is the lead sponsor of 18 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients who have undergone AMI and applied no later than 6 months after discharge from the hospital to the outpatient clinic № 9 or its branches from March 1, 2014 to December 31, 2015;

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients who have undergone AMI and applied no later than 6 months. after discharge from the hospital to the Moscow outpatient clinic № 9 from March 1, 2014, to December 31, 2015;
  • availability of discharge summary with confirmed AMI;
  • permanent residence on the territory of Moscow and the Moscow region;
  • the signing of to the processing of personal data.

Exclusion criteria

Exclusion Criteria:

  • patients with the absence of discharge summary from the hospital with a proven history of AMI;
  • visit the clinic in a period exceeding six months from the AMI;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (actual)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. time to death, recurrent cardiovascular events (AMI, stroke), emergency hospitalization, lifethreatening arrhythmias.

    According to the results of monitoring will be determined a combined endpoint: the death, recurrent cardiovascular events, emergency hospitalization, lifethreatening arrhythmias

    Time frame: 01.03.2014 - through study completion, an average of 5 year

Secondary outcomes

  1. Total mortality

    Determination of total mortality for any reason of patients enrolled in the Registry

    Time frame: 01.03.2014 - through study completion, an average of 5 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Mar 2015, 12 months.

Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's 12 months is below that.

Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2019
First posted
Aug 21, 2019
StartActual
Mar 1, 2014
Primary completionActual
Mar 1, 2015
CompletionActual
Jul 1, 2020
Last update
Jun 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04063176
Lead sponsor
National Research Center for Preventive Medicine
Responsible party
Sponsor
First posted
Aug 21, 2019
Start date
Mar 1, 2014
Primary completion
Mar 1, 2015
Completion
Jul 1, 2020
Last update
Jun 11, 2025

Study contacts

Martsevich Yu Sergey, MD, PhD, professor
study chair · National Research Center for Preventive Medicine
Natalia P Kutishenko
principal investigator · National Research Center for Preventive Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion